ImageneBio Inc

IMA

$4.89

-1.51%

N/A-$0.08

Healthcare

Biotechnology

NASDAQ

Active Trading

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, ...

Key Metrics of IMA

Snapshot

Latest / TTM · 6 periods

Market Cap

$55.10M

ROCE

-40.5%

EV / EBITDA

0.71x

-6.3% YoY

FCF Yield

-104.8%

+22.9% YoY

Cash Conversion Cycle

-485.2d

Current Ratio

21.47

Quick take

TTM —

No major risk flags in selected headline metrics.

Key Metrics

Latest / TTM · 6 periods

Valuation trend

Valuation trend table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$451.13M	$96.26M	$82.22M	$23.50M	$37.48M	$55.10M
Enterprise ValueCompany value including debt and cash adjustments.	$225.90M	$42.04M	$-26.94M	$-8.37M	$12.51M	$-37.67M
EV / SalesHow many dollars investors pay per dollar of sales.	7.29x	2.69x	-2.94x	-2.39x	15.64x	0.00x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-6.73x	-0.62x	0.40x	0.24x	-0.28x	0.71x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	6.71	0.80	1.62	0.91	0.56	1.76

Returns + ROCE gauge

ROCE latest

-40.5%

Prev year -34.2%

Returns + ROCE gauge table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-16.4%	-46.8%	-40.2%	-29.0%	-34.1%	-39.0%
ROAProfit generated from total assets.	-13.8%	-39.9%	-35.5%	-25.8%	-29.6%	-34.5%
ROICReturn generated on invested operating capital.	-15.6%	-46.8%	-39.5%	-30.3%	-34.9%	-39.9%
ROCEOperating return on long-term capital used.	-15.5%	-47.0%	-42.4%	-28.3%	-34.2%	-40.5%
Earnings YieldEarnings as a percentage of market value.	-7.6%	-71.4%	-82.9%	-155.6%	-121.0%	-66.5%

Cash flow quality

Cash flow quality table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-62.01M	$-75.54M	$-80.16M	$-46.00M	$-47.84M	$-57.64M
FCFECash flow available to equity holders after debt flows.	$-62.01M	$-75.54M	$-80.16M	$-46.00M	$-32.84M	$-42.73M
FCF YieldFree cash flow divided by market capitalization.	-13.7%	-78.5%	-97.5%	-195.8%	-127.6%	-104.8%
Income QualityHow well accounting earnings are backed by cash flow.	1.77	1.08	1.17	0.93	0.91	1.10
Capex / OCFShare of operating cash flow spent on capital expenditures.	-2.9%	-1.9%	-0.5%	0.0%	0.0%	0.0%

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	0.0d	0.0d	0.0d	0.0d	591.3d	0.0d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DPOAverage days the company takes to pay suppliers.	18.5d	11.9d	739.3d	214.6d	508.5d	485.2d
Operating CycleTime from buying inventory to collecting receivables.	0.0d	0.0d	0.0d	0.0d	591.3d	0.0d
Cash Conversion CycleNet days cash is tied in operations.	-18.5d	-11.9d	-739.3d	-214.6d	82.8d	-485.2d

Snapshot

Latest / TTM: —

Market Cap

$55.10M

ROE

-39.0%

FCF Yield

-104.8%

Current Ratio

21.47

Supply Chain of IMA

Upstream / Downstream / Proxies

Upstream

WuXi Biologics (Cayman) Inc.HKEx:2269 HUTCHMED (China) LimitedNASDAQ:HCMContract Research Organizations (CROs) - Multiple UnnamedClinical Trial Sites & Investigator NetworksRaw Material & Reagent Suppliers (Unnamed)WuXi AppTec Co., Ltd.HKEx:2359

Downstream

Patients (Moderate-to-Severe Atopic Dermatitis)HUTCHMED (China) LimitedNASDAQ:HCMPotential Future Big Pharma Commercialization Partner

Proxies

Apogee Therapeutics, Inc.NASDAQ:APGE AnaptysBio, Inc.NASDAQ:ANAB ACELYRIN, INC.NASDAQ:SLRN MoonLake ImmunotherapeuticsNASDAQ:MLTX

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer